ApicHope Pharmaceutical Group Co., Ltd. (SHE:300723)
China flag China · Delayed Price · Currency is CNY
35.59
-1.01 (-2.76%)
Sep 4, 2026, 3:04 PM CST

SHE:300723 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
835.63919.381,4192,4892,2752,195
Other Revenue
4.5612.8930.7614.044.953.82
840.19932.271,4502,5032,2802,199
Revenue Growth
-25.08%-35.72%-42.07%9.79%3.68%31.26%
Cost of Revenue
382.5416.76576.21481.98300.2321.98
Gross Profit
457.69515.51874.022,0211,9801,877
Selling, General & Admin
610.02669.32829.711,4141,4641,447
Research & Development
151.89157.25312.09301.37189.78142.32
Other Operating Expenses
-13.3316.5224.3572.8630.3930.44
Operating Expenses
743.84842.521,1671,7921,6851,621
Operating Income
-286.14-327.01-293.44229.35294.58256.25
Interest Expense
-12.45-57.79-35.11-37.65-28.96-38.51
Interest & Investment Income
552.176.353.7211.718.4628.96
Currency Exchange Gain (Loss)
-0.09-0.111.31-5.510.1-0.47
Other Non Operating Income (Expenses)
-83.9-1.03-3.28-1.27-1.78-6.41
EBT Excluding Unusual Items
169.59-379.58-326.79196.63272.4239.82
Impairment of Goodwill
---11.03---
Gain (Loss) on Sale of Investments
-43.07-43.07-40.11-24.64-28.3123.96
Gain (Loss) on Sale of Assets
-0.33-1.161.270.120.19-0.07
Asset Writedown
-4.08-4-15.85-1.02-0.45-1.34
Other Unusual Items
60.0958.36-253.273.0982.59100.4
Pretax Income
182.2-369.45-645.71244.19326.41362.77
Income Tax Expense
-30.96-22.99-7992.3964.3269.36
Earnings From Continuing Operations
213.17-346.46-566.71151.8262.1293.41
Minority Interest in Earnings
7.318.6626.6732.8228.5913.5
Net Income
220.47-337.79-540.04184.61290.68306.92
Net Income to Common
220.47-337.79-540.04184.61290.68306.92
Net Income Growth
----36.49%-5.29%36.04%
Shares Outstanding (Basic)
452452452452429422
Shares Outstanding (Diluted)
452452452452433424
Shares Change
-0.02%0.01%-0.00%4.43%1.94%-2.20%
EPS (Basic)
0.49-0.75-1.200.410.680.73
EPS (Diluted)
0.49-0.75-1.200.410.670.72
EPS Growth
----39.18%-7.09%39.10%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Free Cash Flow
66.11-81.19-870.18123.59-130.25-123.13
Free Cash Flow Per Share
0.15-0.18-1.930.27-0.30-0.29
Dividend Per Share
---0.2100.1330.133
Dividend Growth
---57.54%0%43.95%
Gross Margin
54.47%55.30%60.27%80.75%86.83%85.36%
Operating Margin
-34.06%-35.08%-20.23%9.16%12.92%11.65%
Profit Margin
26.24%-36.23%-37.24%7.37%12.75%13.96%
Free Cash Flow Margin
7.87%-8.71%-60.00%4.94%-5.71%-5.60%
EBITDA
-111.6-135.05-110.38387.34366.46305.79
EBITDA Margin
-13.28%-14.49%-7.61%15.47%16.07%13.91%
D&A For EBITDA
174.54191.96183.06157.9971.8949.54
EBIT
-286.14-327.01-293.44229.35294.58256.25
EBIT Margin
-34.06%-35.08%-20.23%9.16%12.92%11.65%
Effective Tax Rate
---37.84%19.70%19.12%
Revenue as Reported
348.47932.271,4502,5032,2802,199